Listed

Neurocrine Biosciences Inc

NBIXNasdaqCIK 914475HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$959.0mRevenue, Q2 FY2026, three months to 2026-06-30$959.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Jul 31, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$959.0mRevenue, Q2 FY2026, three months to 2026-06-30$959.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure+39.5% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin15.8%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $151.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Revenue: $959.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure−5.4 pts on a year earlier
  • Net margin15.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $144.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Revenue: $959.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure−0.6 pts on a year earlier
  • Diluted EPS$1.39Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure+31.1% on a year earlier
  • Free cash flow$128.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $136.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-31, accession 0000914475-26-000037. Derived: 6-month figure less the 3-month figure.Capital expenditure: $7.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-31, accession 0000914475-26-000037. Derived: 6-month figure less the 3-month figure.Report this figure+43.7% on a year earlier

Last eight quarters

Full statements
Revenue$959.0mOperating margin 15.8%
Diluted EPS$1.39, Q2 FY2026
Free cash flow$128.6m, Q2 FY2026
Neurocrine Biosciences Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m622Revenue, Q3 FY2024, three months to 2024-09-30$622.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Report this figure628Revenue, Q4 FY2024, three months to 2024-12-31$627.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Report this figure573Revenue, Q1 FY2025, three months to 2025-03-31$572.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure688Revenue, Q2 FY2025, three months to 2025-06-30$687.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure795Revenue, Q3 FY2025, three months to 2025-09-30$794.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Report this figure806Revenue, Q4 FY2025, three months to 2025-12-31$805.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Report this figure815Revenue, Q1 FY2026, three months to 2026-03-31$814.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure959Revenue, Q2 FY2026, three months to 2026-06-30$959.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%29.5%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $183.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Revenue: $622.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Report this figure22.6%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $142.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Revenue: $627.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Report this figure4.1%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $23.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Revenue: $572.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure21.2%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $145.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Revenue: $687.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure30.1%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $239.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Revenue: $794.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Report this figure26.2%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $210.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Revenue: $805.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Report this figure23.7%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $193.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Revenue: $814.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure15.8%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $151.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Revenue: $959.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure
Net margin%20.9%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $129.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Revenue: $622.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Report this figure16.4%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $103.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Revenue: $627.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Report this figure1.4%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $7.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Revenue: $572.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure15.6%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $107.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Revenue: $687.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure26.4%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $209.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Revenue: $794.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Report this figure19.1%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $153.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Revenue: $805.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Report this figure24.3%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $197.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Revenue: $814.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure15.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $144.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Revenue: $959.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure
Diluted EPS$ per share1.24Diluted EPS, Q3 FY2024, three months to 2024-09-30$1.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Report this figurenot reported (Diluted EPS not reported)0.08Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure1.06Diluted EPS, Q2 FY2025, three months to 2025-06-30$1.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure2.04Diluted EPS, Q3 FY2025, three months to 2025-09-30$2.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-28, accession 0000914475-25-000181.Report this figurenot reported (Diluted EPS not reported)1.91Diluted EPS, Q1 FY2026, three months to 2026-03-31$1.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure1.39Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0000914475-26-000037.Report this figure
Free cash flow$m150Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $158.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-28, accession 0000914475-25-000181. Derived: 9-month figure less the 6-month figure.Capital expenditure: $8.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-28, accession 0000914475-25-000181. Derived: 9-month figure less the 6-month figure.Report this figure235Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $242.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Capital expenditure: $7.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Report this figure54.1Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $64.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Capital expenditure: $10.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure89.5Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $102.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-31, accession 0000914475-26-000037. Derived: 6-month figure less the 3-month figure.Capital expenditure: $12.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-31, accession 0000914475-26-000037. Derived: 6-month figure less the 3-month figure.Report this figure214Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $227.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-28, accession 0000914475-25-000181. Derived: 9-month figure less the 6-month figure.Capital expenditure: $13.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-28, accession 0000914475-25-000181. Derived: 9-month figure less the 6-month figure.Report this figure386Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $388.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Capital expenditure: −$2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000914475-26-000007. Derived: 12-month figure less the 9-month figure.Report this figure137Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $145.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Capital expenditure: $9.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0000914475-26-000026.Report this figure129Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $136.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-31, accession 0000914475-26-000037. Derived: 6-month figure less the 3-month figure.Capital expenditure: $7.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-31, accession 0000914475-26-000037. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$2.86bnOperating margin 21.6%
Diluted EPS$4.67, FY2025
Free cash flow$748.7m, FY2025
Neurocrine Biosciences Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m1,134Revenue, FY2021, twelve months to 2021-12-31$1.13bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-09, accession 0000914475-24-000054.Report this figure1,489Revenue, FY2022, twelve months to 2022-12-31$1.49bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-10, accession 0000914475-25-000037.Report this figure1,887Revenue, FY2023, twelve months to 2023-12-31$1.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure2,355Revenue, FY2024, twelve months to 2024-12-31$2.36bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure2,861Revenue, FY2025, twelve months to 2025-12-31$2.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%9.0%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $102.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-09, accession 0000914475-24-000054.Revenue: $1.13bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-09, accession 0000914475-24-000054.Report this figure16.7%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $249.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-10, accession 0000914475-25-000037.Revenue: $1.49bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-10, accession 0000914475-25-000037.Report this figure13.3%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $250.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007.Revenue: $1.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure24.2%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $570.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007.Revenue: $2.36bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure21.6%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $619.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007.Revenue: $2.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure
Net margin%7.9%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $89.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-09, accession 0000914475-24-000054.Revenue: $1.13bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-09, accession 0000914475-24-000054.Report this figure10.4%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $154.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-10, accession 0000914475-25-000037.Revenue: $1.49bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-10, accession 0000914475-25-000037.Report this figure13.2%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $249.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007.Revenue: $1.89bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure14.5%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $341.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007.Revenue: $2.36bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure16.7%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $478.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000914475-26-000007.Revenue: $2.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure
Diluted EPS$ per share0.92Diluted EPS, FY2021, twelve months to 2021-12-31$0.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-09, accession 0000914475-24-000054.Report this figure1.56Diluted EPS, FY2022, twelve months to 2022-12-31$1.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-10, accession 0000914475-25-000037.Report this figure2.47Diluted EPS, FY2023, twelve months to 2023-12-31$2.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure3.29Diluted EPS, FY2024, twelve months to 2024-12-31$3.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure4.67Diluted EPS, FY2025, twelve months to 2025-12-31$4.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure
Free cash flow$m233Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $256.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-09, accession 0000914475-24-000054.Capital expenditure: $23.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-09, accession 0000914475-24-000054.Report this figure323Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $339.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-10, accession 0000914475-25-000037.Capital expenditure: $16.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-10, accession 0000914475-25-000037.Report this figure362Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $389.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000914475-26-000007.Capital expenditure: $28.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure557Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $595.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000914475-26-000007.Capital expenditure: $38.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure749Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $782.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000914475-26-000007.Capital expenditure: $34.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000914475-26-000007.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Neurocrine Biosciences Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$2.31bn13,711,607Added+326,000
JPMORGAN CHASE & CO2026-06-30$1.09bn6,398,674Added+956,607
Dodge & Cox2026-06-30$941.2m5,584,707Added+123,670
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$838.3m4,974,083Added+247,739
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$766.0m4,545,339Added+33,435
STATE STREET CORP2026-06-30$739.1m4,385,598Added+31,072
AQR CAPITAL MANAGEMENT LLC2026-06-30$643.5m3,818,037Reduced−1,120,930
RENAISSANCE TECHNOLOGIES LLC2026-06-30$393.7m2,335,897Reduced−83,000
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$359.6m2,138,777Added+2,105
TWO SIGMA INVESTMENTS, LP2026-06-30$349.9m2,076,260Reduced−984,310

Recent filings

All 1,675 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Neurocrine Biosciences Inc, recent filings
FiledFormWhat it isAccession number
2026-09-2816:20 ET8-K5.02 Departure or appointment of officers or directors0000914475-26-000045
2026-07-3116:05 ET8-K/A9.01 Financial statements and exhibits0001193125-26-328470
2026-07-3121:22 ET10-QQuarterly reportPeriod 2026-06-300000914475-26-000037
2026-07-3016:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000914475-26-000035
2026-05-2816:01 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results0000914475-26-000029
2026-05-1809:04 ET8-K1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-228013
2026-05-0516:02 ET10-QQuarterly reportPeriod 2026-03-310000914475-26-000026
2026-05-0516:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000914475-26-000025
2026-04-1516:15 ETDEF 14AProxy statementPeriod 2026-04-150000914475-26-000015
2026-04-0607:35 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001193125-26-142904

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 11, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
914475
Tickers
NBIX
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 13:54 ET. Listed shows no prices and gives no investment advice.